When executed with precision and transparency, ECAs can enhance trial efficiency, expand access and support evidence—while ...

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

A recent study found that a single-dose treatment with the drug baloxavir led to a significantly reduced transmission of influenza to close contacts.

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

Objectives To identify and assess the social support interventions provided to caregivers of older adults with dementia. By ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today ...

In May, the MPA/ID program celebrated its 25-year anniversary with a reunion on the Harvard Kennedy School campus of over 350 ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

Trial registration number NCT05920304. The randomised controlled trial (RCT) has been preceded by usability and feasibility studies that have informed the design of the RCT including ... Percentage of ...